Courage Against Cancer
The future of cancer treatment lies in combination. Discover the compelling science suggesting how repurposed drugs like ivermectin and mebendazole could work synergistically with standard therapies to improve outcomes and overcome treatment resistance.
G’day mates — it’s me, Coco the Koala, and I can hardly contain my excitement! Today’s a historic moment for our Courage Against Cancer family. 🧬
We’ve just submitted our very first Sponsored Research Agreement (SRA) to MD Anderson Cancer Center — one of the world’s leading institutions in cancer research. Together, we’re launching a preclinical trial studying ivermectin and mebendazole as potential treatments against ovarian cancer.
It’s the first courageous step toward FDA-approved, non-chemotherapy cancer therapies — and I’m beaming with hope! Stay tuned as we climb this new branch of discovery, one brave leaf at a time.
Stay Courageous, mates. Healing is possible.
— Coco the Koala 🐨
Repurposing existing drugs like ivermectin and mebendazole offers a groundbreaking path forward in the war against cancer. Learn how Courage Against Cancer’s preclinical work on ovarian cancer may help establish the safety, mechanisms, and efficacy of these overlooked therapies — and how you can help us bridge science and compassion in the fight for human healing.
In the face of a growing cancer crisis, the urgent need for alternative treatment options has become increasingly clear. This article examines the limitations of conventional therapies like chemotherapy and radiation and why embracing non-traditional treatments, such as those involving Ivermectin and Mebendazole, is crucial for enhancing patient outcomes and quality of life. By diversifying treatment options, we can provide hope to patients and families during their most challenging times.
Courage Against Cancer announces a new preclinical research initiative studying ivermectin and mebendazole against ovarian cancer. Learn what science currently shows about these repurposed antiparasitic drugs — and why this research may change the future of cancer therapy.
In recent years, two existing drugs—Ivermectin and Mebendazole—have captured the attention of researchers and healthcare professionals alike for their potential anti-cancer effects. As the quest for non-chemotherapy, non-radiation therapies advances, understanding how these drugs could reshape cancer treatment is becoming increasingly vital. This article delves into the science behind IVM and MBZ, illuminating their mechanisms, available research, and the promise they hold for the future of oncology.
Courage Against Cancer announces a major milestone: funding our first preclinical trial for ivermectin and mebendazole. This is the critical first step on our rigorous path to achieve FDA approval and create a new, accessible paradigm in cancer therapy.
Courage Against Cancer 